2020
Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
Schalper KA, Carleton M, Zhou M, Chen T, Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, Locke D, Wu Q, Reilly TP, Phillips P, Nagineni V, Gianino N, Gu J, Zhao H, Perez-Gracia JL, Sanmamed MF, Melero I. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nature Medicine 2020, 26: 688-692. PMID: 32405062, PMCID: PMC8127102, DOI: 10.1038/s41591-020-0856-x.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalBiomarkers, PharmacologicalBiomarkers, TumorCell Cycle CheckpointsCohort StudiesFemaleHumansInterleukin-8MaleNeoplasmsNeutrophil InfiltrationNeutrophilsPrognosisProtein Kinase InhibitorsRetrospective StudiesSurvival AnalysisTreatment FailureTumor MicroenvironmentUp-RegulationConceptsSerum IL-8 levelsImmune checkpoint inhibitorsIL-8 levelsAdvanced cancerSerum interleukin-8 levelsPhase 3 clinical trialsSerum interleukin-8Interleukin-8 levelsLarge-scale retrospective analysisNeutrophil infiltrationWorse prognosisClinical benefitPoor outcomeIndependent biomarkerTumor immunobiologyClinical trialsInterleukin-8Retrospective analysisPatientsCancerInhibitorsIpilimumabNivolumabEverolimusPrognosis
2019
Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma
Guerra MT, Florentino RM, Franca A, Lima Filho AC, Dos Santos ML, Fonseca RC, Lemos FO, Fonseca MC, Kruglov E, Mennone A, Njei B, Gibson J, Guan F, Cheng YC, Ananthanarayanan M, Gu J, Jiang J, Zhao H, Lima CX, Vidigal PT, Oliveira AG, Nathanson MH, Leite MF. Expression of the type 3 InsP3 receptor is a final common event in the development of hepatocellular carcinoma. Gut 2019, 68: 1676. PMID: 31315892, PMCID: PMC7087395, DOI: 10.1136/gutjnl-2018-317811.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsApoptosisCalcium SignalingCarcinogenesisCarcinoma, HepatocellularCell ProliferationCells, CulturedDNA MethylationFemaleGene Expression Regulation, NeoplasticHepatocytesHumansInositol 1,4,5-Trisphosphate ReceptorsLiverLiver NeoplasmsLiver RegenerationMaleMice, KnockoutMiddle AgedSurvival AnalysisConceptsChronic liver diseaseITPR3 expressionLiver cancer cellsLiver diseaseMouse modelFinal common eventCancer cellsSpecimens of patientsIndependent patient cohortsControl liver specimensHuman HCC cellsType 3 InsP3 receptorHuman liver samplesIncreased expression levelCancer deathPatient cohortCommon molecular eventPoor survivalHepatocellular carcinomaLiver specimensNormal liverHCC cellsAbstractTextHCCType 3 isoform